In the News
2017 MSK Cardio-Oncology Symposium
Admin • CCON • 5/3/2017
2017 MSK Cardio-Oncology Symposium: Cardiovascular Health and Disease During and After Cancer Therapy – A Case Based Curriculum Date & Location Friday, May 12, 2017 7:00 AM – Saturday,... Read more »
Read More...Cardio-Oncology in China – A New Frontier!
Admin • CCON • 12/15/2016
From the first Cardio-Oncology workshop in June 2016 to a national meeting in November, the First Affiliated Hospital of Dalian Medical University in partnership with Peony Solutions, accelerates growth of... Read more »
Read More...ACC Cardio-Oncology Course
Admin • CCON • 10/28/2016
Register today and save for the inaugural Advancing Cardiovascular Care of the Oncology Patient course. As the patient population with cancer and cancer survivors who have significant cardiovascular risk factors and cardiovascular... Read more »
Read More...Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
Admin • CCON • 7/31/2016
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J,... Read more »
Read More...Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter
Admin • CCON • 2/2/2016
Chau T. Dang, Anthony F. Yu, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis Journal of Clinical Oncology Published online before print. February 1, 2016, doi:10.1200/JCO.2015.64.5515JCO February 1, 2016 JCO645515 Read Article
Read More...Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies
Admin • CCON • 12/16/2015
REDWOOD CITY, Calif. and PALO ALTO, Calif., Dec. 16, 2015 /PRNewswire/ — Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent... Read more »
Read More...Cardiac Meds Appear to Protect Heart From Herceptin Damage
Admin • CCON • 12/15/2015
SAN ANTONIO ― Breast cancer patients treated with trastuzumab (Herceptin, Genentech, Inc) had significantly lower risk for left ventricular (LV) dysfunction and consequent treatment interruptions when treated prophylactically with heart... Read more »
Read More...KU hospital program promotes heart health for cancer patients
Admin • CCON • 12/14/2015
KANSAS CITY, Kan. —A program at the University of Kansas Hospital is now combining cardiology and oncology. Read More
Read More...Mixed Results for Herceptin Cardiotoxicity Prevention
Admin • CCON • 12/10/2015
Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »
Read More...Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer
Admin • CCON • 12/9/2015
SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »
Read More...